Video

Extended Follow-up Results From CheckMate 274: Adjuvant Nivolumab in MIUC

Author(s):

Matthew D. Galsky, MD

Expert Matthew D. Galsky, MD, shares his perspective on follow-up results from CheckMate 274, which analyzed adjuvant nivolumab in patients with high-risk muscle-invasive urothelial carcinoma.

Related Videos
Alberto Montero, MD, MBA, CPHQ
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Thomas Westbrook, MD, assistant professor, Rush University Medical Center
David A. Braun, MD, PhD
Ami Umesh Badami, MD
Janaki Neela Sharma, MD, assistant professor, clinical medicine, Genitourinary Medical Oncology, University of Miami Health Systems
Phase 3 MIRASOL Trial: Updated Overall Survival Results of Mirvetuximab Soravtansine (MIRV) Versus Investigator’s Choice (IC) Chemotherapy in Patients (pts) With Platinum-Resistant Ovarian Cancer (PROC) and High Folate Receptor-Alpha (FR⍺) Expression
Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Alan Tan, MD
Yair Lotan, MD, UT Southwestern Medical Center
Related Content
Gautier Marcq, MD
November 7th 2024

Padeliporfin VTP Maintains Robust Responses and is Safe in Low-Grade Upper-Tract Urothelial Cancer

Oncology Unplugged
November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.
November 2nd 2024

The OncFive: Top Oncology Articles for the Week of 10/27

Oncology Unplugged
August 7th 2024

Park and Grivas Expand on Treatment Updates in Bladder Cancer

ESMO 2024
November 1st 2024

The Top News From ESMO 2024: A Variety of Data Inform Solid Tumor Landscapes

FDA
October 31st 2024

FDA Grants Regenerative Medicine Advanced Therapy Designation to ALLO-316 in CD70+ Advanced RCC